BiotechTube
HALIX BV

HALIX BV

Leiden, Netherlands· Est.
halix.nl
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $20.5M

Overview

HALIX is a specialized biologics CDMO with a strong track record in mammalian cell culture for viral vectors and recombinant proteins. Founded in 2012, it has successfully delivered commercial-scale manufacturing, most notably for the AstraZeneca COVID-19 vaccine, demonstrating its commercial capabilities. The company serves over 75 clients, from small startups to big pharma, with a 90% retention rate, and offers flexible, end-to-end services from process development to aseptic fill/finish. Its modern, 6,700 m² facility in Leiden is designed for scalability and compliance with major regulatory standards.

BiologicsVaccines

Technology Platform

Mammalian cell culture platform for end-to-end development and GMP manufacturing of viral vectors (AAV, Adenovirus, Influenza) and recombinant proteins (mAbs, bispecifics, biosimilars). Includes upstream (up to 1000L), downstream purification, and aseptic fill/finish capabilities.

Funding History

2
Total raised:$20.5M
Debt$12M
Grant$8.5M

Opportunities

The growing outsourcing trend in biopharma, especially for complex biologics like viral vectors and advanced proteins, presents a significant market opportunity.
Increased focus on pandemic preparedness and regional vaccine supply chains also drives demand for its vaccine manufacturing expertise.
The facility's design allows for ready expansion to meet increasing client needs.

Risk Factors

Operational risk is concentrated in a single facility, making the business vulnerable to disruptions.
The company faces intense competition from larger, global CDMOs and must continuously demonstrate differentiated value.
Regulatory non-compliance or failure to pass critical audits could severely impact operations and reputation.

Competitive Landscape

HALIX competes in a crowded global CDMO market against large, multi-site players like Lonza, Catalent, and Samsung Biologics, as well as other European specialists. Its competitive differentiation lies in its mammalian-focused expertise, end-to-end services from a single site, proven commercial vaccine scale, and a partnership-oriented approach tailored for both small biotechs and large pharma.

More companies in Biologics / Biosimilars →More companies in Netherlands →